Home › Bronchiolitis Obliterans Syndrome › NCT05919511
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
RecruitingObservational study
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age ≥ 18 years inclusive at the time of signing the ICF * Allogeneic SCT 90 to 180 days prior to enrollment * Able to comprehend and willing to provide informed consent * Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel Exclusion Criteria: * There are no exclusion criteria for this study
About the study
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
What is being tested
- Non-Interventional (other)
Sponsor: Incyte Corporation · Participants: 1,500 · Started: Aug 1, 2023
Contact the study team
- Incyte Corporation Call Center (US) · Phone: 1.855.463.3463
- Incyte Corporation Call Center (ex-US) · Phone: +800 00027423
Official record on ClinicalTrials.gov — NCT05919511
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.